ARGENX SE-ADR (ARGX) Getting Somewhat Favorable News Coverage, Analysis Finds
Press coverage about ARGENX SE-ADR (NASDAQ:ARGX) has trended somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. ARGENX SE-ADR earned a news impact score of 0.08 on Accern’s scale. Accern also assigned news articles about the company an impact score of 46.3336552798781 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Separately, Cowen and Company reaffirmed a “buy” rating on shares of ARGENX SE-ADR in a report on Thursday, August 24th.
Shares of ARGENX SE-ADR (NASDAQ:ARGX) traded down 1.69% during trading on Tuesday, reaching $24.38. The company had a trading volume of 19,678 shares. The company’s market capitalization is $655.11 million. ARGENX SE-ADR has a 52-week low of $17.33 and a 52-week high of $27.25. The firm has a 50-day moving average price of $22.50 and a 200-day moving average price of $21.30.
WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/17/argenx-se-adr-argx-getting-somewhat-favorable-news-coverage-analysis-finds.html.
About ARGENX SE-ADR
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The companys lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
Receive News & Stock Ratings for ARGENX SE-ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARGENX SE-ADR and related stocks with our FREE daily email newsletter.